Main Web Site : www.henderson-morley.com

On line shop web site : http://www.herpesexpert.com (Frost and Simpson)

Investor Relations email : investors@henderson-morley.com

Henderson Morley is a drug discovery company

The company has been developed specifically to carry out preliminary sourcing and screening of candidates to combat diseases caused by the herpes family of viruses and certain other DNA viruses

Latest GECR update 15th October 2006

Latest GE&CR update - 15th Oct 2006 :


The news investors have all been waiting for - regarding negotiations with a US dermatological pharmaceutical firm has finally been unveiled. The licence has been granted under an agreement to
Cutanea, a U.S. pharmaceutical company, specialising in the development of dermatology products in the US market.

The licence is for new applications of ICVT for the treatment of dermatological conditions in humans. The agreement and takes the form of an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence. Under the terms of the Agreement, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter.

Under its business plan, Henderson Morley has stated its belief that, following clinical development and regulatory licence approval, sales of the product in excess of $1.5 billion could be achieved over the subsequent ten year period. This would give a potential royalty to Henderson Morley in excess of $115 million over this term.

As a drug discovery company, it is imperative that Henderson continues to grant licenses to further develop its technology portfolio. This is the group's third ICVT license agreement. Encouragingly, Cutanea has a great management team with a proven track record of commercialising dermatology products.

Meanwhile, the company has announced that it has been working away on a vaccine against Koi Carp Herpes virus. The group believes it is now ready to start field trials of a
candidate vaccine, in a collaboration with the Internationally renowned Hagerman
Aquaculture Research Institute in Idaho USA. The initial immunogenicity studies should produce results within 6 months, enabling Henderson Morley scientists to optimise the vaccine formulation, with a view to securing a product licence from the veterinary authorities as soon as practicable.

Clearly activity at Henderson Morley has been significant in recent weeks. The licensing announcement is very encouraging, but with the news now out of the way, the shares have eased - a classic case of buy on the rumour, sell on the news. That said, the stock has now pulled back below the recent placing price. With so much going on at the company, further newsflow in the shorter term is far from unlikely.

*Henderson Morley is a corporate client of Bishopsgate Communications which is owned by RSH, the ultimate owner of GE&CR.

Forecasts and a formal recommendation are suspended ahead of the publication of a detailed note next month.

1.5 Mil Sells & only 200,000 Buys so far today & yet the price still holding firm. Seems to be some good support around this level now.

Does anyone know why HML has gone up by 17% this morning?

I think some news maybe expected Marcel

Keith

Henderson Morley PLC
28 February 2007
HENDERSON MORLEY PLC
(AIM:HML)

KOI CARP VACCINE UPDATE

The Board of Henderson Morley plc ('Henderson Morley' or 'the Company'), the AIM
listed drug discovery company, is pleased to provide the market and its
shareholders with an update in respect of the studies relating to the Koi Carp
vaccine following the announcement made on 3 October 2006.

These studies were designed to establish if the vaccine candidate is able to
boost the immune system of vaccinated fish and included dose ranging studies to
determine at what dose the vaccine should be administered. A successful vaccine
should enable Koi exposed to virus, to mount a successful immune response
against KHV and thus prevent disease. These studies examined antibody responses
to vaccination also known as antigenicity studies.

The antigenicity studies of the Koi herpes vaccine candidate have now been
completed. The data has been analysed and the Board is pleased to announce that
100% of the vaccine recipients tested have produced a significant immune
response.

This level of immunity is a very good indicator of a successful vaccine being
developed. Further field studies are ongoing and the Company will keep
shareholders informed of progress in due course.

---ENDS---

Predicted market reaction to a 100% success rate, anybody ?

Not really a good day today issue good news.

HML seems tobe quiet a bit of buying does anyone know why?

nope .... must be nutters with too much money

New monthly GE&CR update just out.



Henderson Morley, the AIM listed drug discovery company has issued an update on studies relating to the Koi Carp vaccine following an announcement made in October last year. The studies were designed to establish if the vaccine is able to boost the immune system of vaccinated fish. It included dose ranging studies to determine the exact dosage that could be administered. If successful, Koi fish exposed to virus should be able to mount a successful immune response against KHV and prevent disease. Analysis has revealed that the 100% of the vaccine recipients tested have produced a significant immune response.

This update follows news of an agreement with AIM-listed Stem Cell Sciences, which allows SCS to explore the use of HM's L-particles and PREPS technology in the design of unique stem cell based assays.
The recently completed Cutanea Licence Agreement for new applications of ICVT, for the treatment of dermatological conditions on human, is set to boost Henderson Morleys cashflow by up to US$6.675 million over the course of the deal. This will strengthen the companys balance sheet and finance its development further, resulting in more licence deals and the undertaking of more research programmes with partners in the industry. The companys prospects remain good and we continue to believe that the share price at just over 2p does not reflect the upside potential of the companys drug research and discovery licence agreements and on-going progress it has made over the last year.
Henderson Morley offers a diverse range of novel therapeutic drug development opportunities. Its patent protected intellectual property in relation to virus infections shows evidence of having wide application, particularly with regard to vaccines for serious diseases including cancer.
We have valued the Company on a heavily risk-weighted DCF-based valuation at 4.2p per share and, with the shares trading at 2.03p, this suggests upside potential of over 80%. Any further operational progress, both in terms of drug trials and in the granting of additional licences, will reduce our risk weightings on the product development portfolio and add to that core valuation. On that basis, our stance remains buy at 2.03p.

A conference being held Wednesday, May 16

Henderson morley are speakers.

http://www.pegsummit.com/07-PDL.asp

5:20 Henderson Morley
PREPS and L-Particles- A Novel Herpes Simplex Based Virus Like Particle For Delivery of a Wide Range of Therapeutic Proteins
Dr Ian Pardoe, MB ChB, Chief Executive and Medical Director, Henderson Morley plc.
It is a little known fact, that as part of the natural infectious cycle, herpes simplex viruses produce virus like particles in culture. These particles contain all of the surface and tegument proteins of the parent virus, but completely lack the nucleocapsid. These so called L-particles facilitate the natural infection of HSV, so are able to enter cells as if they were viruses. Because of the total lack of DNA, they are unable to replicate. The intellectual property regarding production of L-particles, and a further refinement; PREPS is owned by Henderson Morley and they are now being developed as therapeutic agents. Non native proteins that have been engineered into the parent virus, can be delivered functionally intact to cells. It is possible to engineer the virus to express several antigens simultaneously, so a multivalent cancer vaccine is therefore being developed. L-particles also enhance naked DNA transfection, hence its use as an adjuvant for DNA vaccines is being explored. This talk will briefly highlight the technology and its potential applications.

Some buying going on, up about 5% now don't know the reason yet

A conference being held Wednesday, May 16

May have some thing to do with it.

Roomers by the look of it, reading the other side.

I'm impatient so I've sold mine for other picks but I heard the take over talk as well around 8p--but it's a very long time coming!

Good volume today some rather big buys, it would be nice if we had some news to back the rise up or could it be another false dawn
The pattern over the weeks and months is now predictable up and down , with so many products in the pipeline it may just be a matter of time and patience

This share has been a disaster for years is there any Management intention of making it profitable, or is it a means to keep them emplopyed?
You would think that having patented a scheme they's strive to prove its worth; conduct trials on patients etc. and there has been enough time for this since about 2000, when they first listed (on Ofex, I suspect, but can't be certain).
Since coming to AIM there has been no real progress...as far as I recall....so just what are we waiting for? - and on past performance just how long will it be "in coming?" I suspect this is another never-never investment.....the World will be cured of cancer by the time anyone wakes up to this treatment.....that is if it is a treatment...or is it just a "delivery" like Tetrapac waiting in some parallel World for milk to become popular?
I have held this and you know, I'm getting rather sick of it...

KKeith2000 keeps us (here) up to date...but it's just words on the page....I don't see any commercial result....and Koi Carp are pretty ugly, couldn't they have chosen herring, the little sweeties?

hangon some of the things you say are correct but with the small caps it can sometimes work like this, a little buying lifts the s/p we all hope for news it doesn't come the personal investors get board give them back to the mm/s and the s/p drifts down
I do think we will have some good news sometime but when i don't know, some of the products the company have could be worth millions so in the meantime i will wait till i get board

Looks to be on the move, no news yet but over the past few weeks some large buying, after the risers and falls just wondering if this time we could just rise up to the final results which i think out next month and some good news

Henderson Morley PLC
20 June 2007

20 JUNE 2007

HENDERSON MORLEY PLC
(AIM:HML)

SCIENTIFIC PROGRAMME UPDATE

The Board of Henderson Morley plc ('Henderson Morley' or 'the Company'), the AIM
listed drug discovery company, is pleased to provide the market and their
shareholders with an update detailing the current status of the Company's
activities and its scientific pipeline.

HIGHLIGHTS

Discussions with a pharmaceutical partner regarding Koi Herpes vaccine at
an advanced stage;

Internationally renowned consultant retained to assist the development of
PREPS and L-particles;

It is envisaged that a final injectable formulation of ICVT will be ready
for Pre-IND discussions with the FDA by December 2007;

A specialist animal health Contract Research Organisation contracted to
undertake field studies to examine the use of ICVT topical drops in the
treatment of Feline Herpes Virus (FHV) conjunctivitis;

The first phase of the Henderson Morley's laboratory expansion is now
complete - resulting in a newly formed Molecular Virology Lab, enhanced
virus growth capabilities

Executive Chairman Andrew Knight said: 'We are continuing to see strong interest
across the portfolio as it develops. We look forward to further updating the
market in due course.'

---ENDS---

ENQUIRIES:

HENDERSON MORLEY PLC 0121 442 4600
Andrew Knight, Chairman

BISHOPSGATE COMMUNICATIONS LTD 0207 562 3350
Maxine Barnes
Nick Rome

BREWIN DOLPHIN SECURITIES LTD 0113 241 0126
Neil Baldwin


SCIENTIFIC PROGRAMME UPDATE

Koi Herpes vaccine

The Company is pleased to announce that it is in late stage discussions with a
pharmaceutical partner in respect of a licence for the vaccine.

The initial immunogenicity studies regarding the Company's proprietary vaccine
against Koi Herpes Virus (KHV) demonstrated potent antibody responses. Further
studies using a virus neutralising assay have shown that not only were
antibodies produced by the vaccine, but these demonstrated virus neutralising
effects.

A reliable immunofluorescence assay has now also been developed, as well as
larger scale virus production and a variety of standardisation and quality
control measures.

Further announcements will be made in due course.

PREPS and L-particles

This technology, which uses non replicating virus particles that totally lack
DNA, was presented to an International Congress on Protein Therapeutics in
Boston (PEGS Summit, Boston InterContinental Hotel, 16 May 2007). This
generated considerable interest within the scientific community and therefore a
further presentation will be made in August at the 2007 Cancer Immunotherapies
Conference in Cambridge Mass., USA.

To advise on the development of this technology, the Company has retained
internationally renowned consultant Professor Lemoine. Professor Lemoine holds
his chair at Queen Mary's School of Medicine (at Barts and the London Hospital)
and is Director of both the Institute of Cancer, and the Cancer Research UK
Clinical Centre. He also leads the Centre for Molecular Oncology.

Laboratory based studies are progressing well, using state of the art virus
engineering techniques to produce viruses that express marker proteins for
immunogenicity studies - a precursor to pre-clinical and clinical studies.

Other in-house studies are also making good progress in exploring the use of
these particles as candidates for human herpes virus vaccines.

ICVT formulation

The development of an injectable formulation of ICVT in conjunction with the
University of Aston, Pharmaceutics department, is nearing completion.
Standardised assays have been developed and initial chemistry and release
studies have also been completed. It is envisaged that a final formulation will
be ready for Pre-IND discussions with the FDA by December 2007.

Feline Herpes

Previous in-vitro studies completed in-house have demonstrated that the Feline
Herpes Virus (FHV) is extremely sensitive to the effects of ICVT. Consequently,
Henderson Morley is pleased to announce that a specialist animal health Contract
Research Organisation has now been contracted to undertake field studies to
examine the use of ICVT topical drops in the treatment of FHV conjunctivitis.

The studies are expected to start within 60 days, with results of the study
anticipated within Q1 2008.

The studies will examine animals that are already infected by FHV. The animals
will be given drops to be applied by their owners or by veterinary health care
professionals. No animals will be harmed in these studies, ethics committee
approval will be gained, and the studies will be supervised by independent
veterinary advisers.

The drops to be used in this study have been shown to be safe and well tolerated
in human studies. If the cats were not enrolled into this study it is likely
that they would remain untreated. If the treatment proves successful, it is
likely therefore that the welfare of the cats treated in this study will be
significantly enhanced, with potential future benefit for the wider feline
community.

Feline herpes virus infections are very common, and represent a major cause of
morbidity in animal care institutions, the wild feline population and domestic
cats, especially at times of breeding.

A recent sero-epidemiolgical study demonstrated that in wild cat populations
feline herpes incidence was as high as 75%. Also in approximately one third of
clinically normal cats, it was possible to isolate virus from their respiratory
tract, and that over 97% of the whole study group had antibodies against FHV-1
by ELISA. This indicates that the infection is extremely common and is prone to
recurrence, even in those animals that are clinically normal.

There is currently no anti-viral treatment licensed to treat feline herpes
infection in the UK or any of the major markets, so a significant market
opportunity exists.

Laboratory Expansion

The first phase of the HML laboratory expansion has now been completed. This has
resulted in a newly formed Molecular Virology Laboratory with enhanced virus
growth capabilities. Virus handling and purification, sterilisation,
inactivation and quality control measures have also been enhanced.

Preliminary Results

The Company will be announcing its results for the year to 30 April 2007 before
30 September 2007.

---ENDS---

ENQUIRIES:

HENDERSON MORLEY PLC 0121 442 4600
Andrew Knight, Chairman

BISHOPSGATE COMMUNICATIONS LTD 0207 562 3350
Maxine Barnes
Nick Rome

BREWIN DOLPHIN SECURITIES LTD 0113 241 0126
Neil Baldwin


Notes to Editors:

Henderson Morley was founded in 1996 with the objective of developing its anti-
viral application (Ionic Contra Viral Therapy (ICVT). ICVT is the Lead Platform
and has been developed in-house and Henderson Morley wholly owns the patent IPR.

Further information on Henderson Morley plc can be accessed through the
Company's website at
www.henderson-morley.com

Its now fair to say until we get a licence for one of the products this share will generate little interest and you can understand why from the past

I do believe the RNS today is positive and for the brave in time will come good, but as always do your own research